The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2...

Area of Science:

• Neuro-oncology
• Molecular pharmacology

Background:

• Glioblastoma multiforme (GBM) is the most common adult primary brain tumor with a poor prognosis.
• Current treatments include surgery, radiation, and chemotherapy, but resistance remains a challenge.

Purpose of the Study:

• To investigate the anti-cancer effects of Silvestrol, an eIF4A inhibitor, on glioblastoma cells.
• To explore the underlying molecular mechanisms and the impact of hypoxia on Silvestrol's efficacy.

Main Methods:

• Treatment of U251 and U87 human glioblastoma cell lines with Silvestrol.
• Assessment of cell proliferation, cyclin D1 expression, and key signaling pathways (AKT/mTOR, ERK1/2).
• Evaluation of Silvestrol's efficacy under hypoxic conditions and HIF1α modulation.

Main Results:

• Silvestrol significantly reduced proliferation and cyclin D1 expression in glioma cells.
• Silvestrol inhibited AKT/mTOR and ERK1/2 signaling pathways.
• Hypoxia counteracted Silvestrol's effects, with HIF1α upregulation rescuing pathway downregulation.

Conclusions:

• Silvestrol exhibits antitumor activity against GBM cells by targeting AKT/mTOR and ERK1/2 pathways.
• Hypoxia-induced HIF1α upregulation represents a resistance mechanism to Silvestrol in GBM.
• Further research into overcoming hypoxia-mediated resistance is warranted for Silvestrol's clinical application.